BioSpace News Archive

VYRSA Technologies, Inc., a specialty medical device company specializing in innovative sacroiliac fusion devices, announced today that, effective November 1, 2022, Earl R. Fender has been appointed to the Board of Directors.

Sino Biological, Inc. is pleased to announce the formal signing of a lease with Hines and initiation of construction on its new Center for Bioprocessing at its Levit Green facility in Houston, Texas USA.

New View Surgical, Inc., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery (MIS), today announced the closure of a $12.1M Series B-1 equity financing round to fund the commercialization of its VisionPort™ System.

The global optogenetics market size reached a significantly robust value in 2020 and is expected to register a notable CAGR over the forecast period.

The global microbial culture market is expected to reach a considerably large market size in 2030 and register a high CAGR over the forecast period.

Treadwell Therapeutics today announced that four abstracts highlighting CFI-402257 and CFI-400945, the Company’s potent and selective inhibitors of TTK and PLK4, respectively, have been accepted for presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS) being held from December 6-10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that it has raised $38 million in a Series A financing, led by Longitude Capital and Northpond Ventures, with additional participation from Menlo Ventures.

Swing Therapeutics, a digital therapeutics company developing evidence-backed treatments for autoimmune and chronic pain conditions, today announced the presentation of research supporting the use of its digital therapeutic to deliver behavioral therapy for fibromyalgia management.

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of the PreludeSYNC EZ™ Radial Compression Device.

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced two poster presentations on OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in development for the treatment of metastatic breast cancer, at the upcoming San Antonio Breast Cancer Symposium (SABCS) meeting being held December 6-10, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.